Last reviewed · How we verify

Viaskin Peanut 250µg — Competitive Intelligence Brief

Viaskin Peanut 250µg (Viaskin Peanut 250µg) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Epicutaneous immunotherapy. Area: Allergy.

phase 3 Epicutaneous immunotherapy Allergy Small molecule Live · refreshed every 30 min

Target snapshot

Viaskin Peanut 250µg (Viaskin Peanut 250µg) — DBV Technologies. Viaskin Peanut 250µg is an epicutaneous immunotherapy that works by gradually increasing tolerance to peanut allergens.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Viaskin Peanut 250µg TARGET Viaskin Peanut 250µg DBV Technologies phase 3 Epicutaneous immunotherapy
DBV712 DBV712 DBV Technologies phase 3 Epicutaneous immunotherapy (EPIT)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Epicutaneous immunotherapy class)

  1. DBV Technologies · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Viaskin Peanut 250µg — Competitive Intelligence Brief. https://druglandscape.com/ci/viaskin-peanut-250-g. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: